AI Generated Image
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
CBS News • • business
Key Points:
- Eli Lilly is suing six companies that sell unauthorized versions of its experimental weight-loss drug retatrutide, aiming to combat a growing illicit market despite the drug still being in clinical trials and unapproved by the FDA.
- The unauthorized sales are driven by telehealth firms, clinics, and online peptide vendors, fueled by promising trial results and social media hype, even though federal law prohibits commercial sale of unapproved drugs.
- The lawsuits target companies advertising retatrutide for "research use" without prescriptions, including peptide vendors and a California med spa, with the drug reportedly supplied by overseas manufacturers.
- Eli Lilly is conducting late-stage trials for retatrutide as a treatment for obesity and type 2 diabetes, planning to seek FDA approval in early 2027, and analysts expect it to be a blockbuster drug.
- Despite Eli Lilly's legal actions and calls for regulatory and law enforcement intervention, the illicit market for retatrutide continues to operate openly with minimal apparent consequences.
